Quest Diagnostics Incorporated $DGX Shares Acquired by Amalgamated Bank

Amalgamated Bank lifted its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 1.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,949 shares of the medical research company’s stock after buying an additional 325 shares during the quarter. Amalgamated Bank’s holdings in Quest Diagnostics were worth $3,943,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in DGX. Pinnacle Bancorp Inc. raised its stake in shares of Quest Diagnostics by 126.9% during the 2nd quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company’s stock worth $27,000 after buying an additional 85 shares during the last quarter. First Horizon Advisors Inc. raised its stake in shares of Quest Diagnostics by 76.6% during the 1st quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company’s stock worth $32,000 after buying an additional 82 shares during the last quarter. AlphaQuest LLC raised its stake in shares of Quest Diagnostics by 18,400.0% during the 2nd quarter. AlphaQuest LLC now owns 185 shares of the medical research company’s stock worth $33,000 after buying an additional 184 shares during the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of Quest Diagnostics during the 2nd quarter worth $35,000. Finally, Larson Financial Group LLC raised its stake in shares of Quest Diagnostics by 101.9% during the 1st quarter. Larson Financial Group LLC now owns 323 shares of the medical research company’s stock worth $55,000 after buying an additional 163 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Trading Up 0.1%

NYSE DGX opened at $175.93 on Monday. Quest Diagnostics Incorporated has a 12 month low of $148.70 and a 12 month high of $197.55. The company has a 50-day moving average of $182.51 and a 200-day moving average of $177.49. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.13 and a quick ratio of 1.04. The company has a market cap of $19.57 billion, a P/E ratio of 20.65, a P/E/G ratio of 2.31 and a beta of 0.56.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, October 21st. The medical research company reported $2.60 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.09. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The company had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same quarter in the prior year, the company posted $2.30 EPS. The company’s quarterly revenue was up 13.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. As a group, equities analysts predict that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, October 20th. Stockholders of record on Friday, October 3rd were paid a dividend of $0.80 per share. The ex-dividend date of this dividend was Friday, October 3rd. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.8%. Quest Diagnostics’s dividend payout ratio is currently 37.56%.

Insider Activity

In other news, SVP Michael E. Prevoznik sold 28,288 shares of the company’s stock in a transaction dated Tuesday, September 23rd. The shares were sold at an average price of $187.12, for a total transaction of $5,293,250.56. Following the completion of the transaction, the senior vice president owned 38,117 shares of the company’s stock, valued at $7,132,453.04. This represents a 42.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gary M. Pfeiffer sold 1,482 shares of the company’s stock in a transaction dated Wednesday, October 22nd. The shares were sold at an average price of $182.40, for a total transaction of $270,316.80. Following the transaction, the director directly owned 29,431 shares of the company’s stock, valued at approximately $5,368,214.40. This represents a 4.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 44,189 shares of company stock valued at $8,157,857 in the last 90 days. 8.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on DGX shares. Morgan Stanley set a $207.00 target price on shares of Quest Diagnostics and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Baird R W downgraded shares of Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 25th. Weiss Ratings restated a “buy (b)” rating on shares of Quest Diagnostics in a research report on Wednesday, October 8th. Mizuho lifted their target price on shares of Quest Diagnostics from $190.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. Finally, Leerink Partners boosted their price target on Quest Diagnostics from $203.00 to $210.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $196.31.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.